Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 5/2020

01-10-2020 | Computed Tomography | Case Report

A case of an enlarged rectal adenoma while achieving a clinical complete response with chemotherapy for advanced rectal cancer

Authors: Yasuyuki Nakamura, Fumikazu Koyama, Kohei Morita, Hiroyuki Kuge, Chiho Ohbayashi, Masayuki Sho

Published in: Clinical Journal of Gastroenterology | Issue 5/2020

Login to get access

Abstract

The effect of chemotherapeutic agents on concomitant colorectal adenomas in patients with advanced colorectal cancer is not clear. We report a case of an enlarged rectal adenoma while achieving a clinical complete response with chemotherapy for an advanced rectal adenocarcinoma. A 78-year-old man was referred to our hospital for evaluation of bloody stools. The clinical diagnosis was an advanced lower rectal adenocarcinoma with para-aortic lymph node metastases, and a sessile polyp on the proximal aspect of the rectal tumor. The rectal adenocarcinoma was treated with chemotherapy, including 1 cycle of capecitabin plus oxaliplatin (CapeOX), 22 cycles of tegafur/gimeracil/oteracil (S-1) plus irinotecan (IRIS), and 1 cycle of tegafur (UFT) plus calcium folinate (LV). One year after the last course of chemotherapy, colonoscopy showed a scar without visible rectal tumor; CT imaging confirmed no para-aortic lymphadenopathy. The patient had a clinical complete response to chemotherapy. In contrast, the polyp increased in size. The polyp was removed by endoscopic mucosal resection (EMR). The pathologic evaluation showed a well-differentiated tubular adenocarcinoma with adenoma localized in the mucosa. No recurrence of the advanced adenocarcinoma or intramucosal adenocarcinoma with adenoma occurred for 2 years after EMR. This case indicates the importance of careful surveillance for synchronous adenomas, even in patients with advanced colorectal cancer.
Literature
1.
go back to reference Sano Y, Tanaka S, Kudo S, et al. Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Dig Endos. 2016;28:526–33.CrossRef Sano Y, Tanaka S, Kudo S, et al. Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Dig Endos. 2016;28:526–33.CrossRef
2.
go back to reference Crispin A, Mansmann U, Munte A, et al. A direct comparison of the prevalence of advanced adenoma and cancer between surveillance and screening colonoscopies. Digestion. 2013;87:170–5.CrossRefPubMed Crispin A, Mansmann U, Munte A, et al. A direct comparison of the prevalence of advanced adenoma and cancer between surveillance and screening colonoscopies. Digestion. 2013;87:170–5.CrossRefPubMed
3.
go back to reference Kahl CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016;150:758–68.CrossRef Kahl CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016;150:758–68.CrossRef
4.
go back to reference Joana MA, Diogo L, Pedro G, et al. Incidence and predictors of adenoma after surgery for colorectal cancer. Eur J Gastroenterol Hepatol. 2017;29:932–8.CrossRef Joana MA, Diogo L, Pedro G, et al. Incidence and predictors of adenoma after surgery for colorectal cancer. Eur J Gastroenterol Hepatol. 2017;29:932–8.CrossRef
5.
go back to reference Hee Seung Lee, Sung Bac Kim, Hyuu Jung Lee, et al. Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer. Gastrointest Endosc. 2018;87:688–94. Hee Seung Lee, Sung Bac Kim, Hyuu Jung Lee, et al. Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer. Gastrointest Endosc. 2018;87:688–94.
6.
go back to reference Valeriote F, van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res. 1975;35:2619–30.PubMed Valeriote F, van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res. 1975;35:2619–30.PubMed
7.
go back to reference Stacey Ricci M, Zong W-X. Chemotherapeutic approaches for tageting cell death pathways. Oncologist. 2006;11:342–57.CrossRefPubMed Stacey Ricci M, Zong W-X. Chemotherapeutic approaches for tageting cell death pathways. Oncologist. 2006;11:342–57.CrossRefPubMed
8.
go back to reference Ohuchi M, Sakamoto Y, Tokunaga R, et al. Increased EZH2 expression during the adeno-carcinoma sequence in colorectal cancer. Oncology Letter. 2018;16:5275–81. Ohuchi M, Sakamoto Y, Tokunaga R, et al. Increased EZH2 expression during the adeno-carcinoma sequence in colorectal cancer. Oncology Letter. 2018;16:5275–81.
9.
go back to reference Uehara K, Hiramatu K, Maeda A, et al. Neoaduvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 phase II trial. Jpn J Clin Oncol. 2013;43:964–71.CrossRefPubMed Uehara K, Hiramatu K, Maeda A, et al. Neoaduvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 phase II trial. Jpn J Clin Oncol. 2013;43:964–71.CrossRefPubMed
10.
go back to reference Hasegawa J, Nishimura J, Mizushima T, et al. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high risk localized rectal cancer. Cancer Chemother Pharmacol. 2014;73:1079–87.CrossRefPubMed Hasegawa J, Nishimura J, Mizushima T, et al. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high risk localized rectal cancer. Cancer Chemother Pharmacol. 2014;73:1079–87.CrossRefPubMed
11.
go back to reference Rivera F, Karthaus M, Hecht JR, et al. Final analysis of the randomized PEAL trial: overall survival and tumor responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis. 2017;32:1179–90.CrossRefPubMedPubMedCentral Rivera F, Karthaus M, Hecht JR, et al. Final analysis of the randomized PEAL trial: overall survival and tumor responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis. 2017;32:1179–90.CrossRefPubMedPubMedCentral
Metadata
Title
A case of an enlarged rectal adenoma while achieving a clinical complete response with chemotherapy for advanced rectal cancer
Authors
Yasuyuki Nakamura
Fumikazu Koyama
Kohei Morita
Hiroyuki Kuge
Chiho Ohbayashi
Masayuki Sho
Publication date
01-10-2020
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 5/2020
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-020-01169-6

Other articles of this Issue 5/2020

Clinical Journal of Gastroenterology 5/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.